Detailed financial statements for CNS Pharmaceuticals, Inc. (CNSP): income statement, balance sheet and cash-flow summary. Track margins, debt, liquidity and profitability trends year over year with up to 20 years of history.
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $5.50, CNSP has negative trailing earnings (P/E not meaningful) and an ROE of -204.25%. Market capitalisation stands at $8M.
Balance sheet quality for CNSP: current ratio of 2.0, net cash position of $6.9M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Income Statement (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | $1955 | $11096 | $13070 | $11756 | $4134 | $3306 | 0 |
| Gross Profit | 0 | 0 | -$1955 | -$11096 | -$13070 | -$11756 | -$4134 | -$3306 | 0 |
| Research & Development | $32638 | $21267 | $1.9M | $5.1M | $9.8M | $9.3M | $14.1M | $9.3M | $9.8M |
| Selling, General & Admin | $182467 | $860520 | $2.0M | $4.4M | $4.7M | $5.6M | $4.8M | $5.6M | $6.2M |
| Operating Expenses | $215105 | $881787 | $3.8M | $9.4M | $14.5M | $14.9M | $18.9M | $14.9M | $16.0M |
| Operating Income | -$516252 | -$881787 | -$3.8M | -$9.5M | -$14.5M | -$14.9M | -$18.9M | -$14.9M | -$16.0M |
| EBITDA | 0 | -$6.5M | -$3.8M | -$9.4M | -$14.5M | -$15.3M | -$18.8M | -$14.8M | -$15.8M |
| Interest Expense | $4257 | $46697 | $44234 | $3264 | $9285 | $7027 | $13805 | $16119 | $15230 |
| Pre-tax Income | -$219362 | -$7.4M | -$3.9M | -$9.5M | -$14.5M | -$15.3M | -$18.9M | -$14.9M | -$15.9M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$526469 | -$7.4M | -$3.9M | -$9.5M | -$14.5M | -$15.3M | -$18.9M | -$14.9M | -$15.9M |
| EPS | $-11997.00 | $-404415.00 | $-212121.00 | $-512208.00 | $-495027.00 | $-336499.00 | $-150114.00 | $-466.44 | $-35.75 |
| EPS (Diluted) | $-11997.00 | $-404415.00 | $-212121.00 | $-512208.00 | $-495027.00 | $-336499.00 | $-150114.00 | $-466.44 | $-35.75 |
| Shares Outstanding (Diluted) | $18 | $18 | $18 | $18 | $29 | $45 | $126 | $31853 | $443369 |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $110543 | $282736 | $7.2M | $14.0M | $5.0M | $10.1M | $548721 | $6.5M | $7.2M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $882539 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $162194 | $588133 | $7.9M | $15.5M | $7.5M | $12.6M | $1.6M | $8.7M | $8.1M |
| Property, Plant & Equipment | 0 | 0 | $18165 | $23431 | $16109 | $5664 | $4933 | $6005 | $17703 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $162194 | $683333 | $7.9M | $15.9M | $8.8M | $13.1M | $1.7M | $8.7M | $8.6M |
| Accounts Payable | $57497 | $128865 | $289499 | $946330 | $1.5M | $3.7M | $5.8M | $2.2M | $3.8M |
| Short-term Debt | $121825 | $316918 | 0 | $439294 | $387794 | $409968 | $300806 | $326072 | $328571 |
| Total Current Liabilities | $220726 | $1.2M | $311000 | $1.9M | $2.1M | $4.9M | $6.1M | $2.5M | $4.1M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $220726 | $1.2M | $311000 | $1.9M | $2.1M | $4.9M | $6.1M | $2.5M | $4.1M |
| Retained Earnings | -$219362 | -$7.6M | -$11.5M | -$20.9M | -$35.0M | -$50.7M | -$69.6M | -$84.4M | -$100.3M |
| Total Equity | -$58532 | -$549298 | $7.6M | $13.9M | $6.6M | $8.1M | -$4.4M | $6.2M | $4.5M |
| Total Debt | $121825 | $316918 | 0 | $439294 | $387794 | $409968 | $300806 | $326072 | $328571 |
| Net Debt | $11282 | $34182 | -$7.2M | -$13.6M | -$4.6M | -$9.6M | -$247915 | -$6.1M | -$6.9M |
| Working Capital | -$58532 | -$644498 | $7.6M | $13.6M | $5.3M | $7.6M | -$4.5M | $6.1M | $4.0M |
Cash Flow (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$219362 | -$7.4M | -$3.9M | -$9.5M | -$14.5M | -$15.3M | -$18.9M | -$14.9M | -$15.9M |
| Depreciation & Amortization | $2342 | 0 | $1955 | $11096 | $13070 | $11756 | $4134 | $3306 | $3918 |
| Stock-based Compensation | $119854 | $110240 | $477096 | $1.3M | $1.7M | $1.2M | $1.0M | $838957 | $187728 |
| Change in Working Capital | $47250 | $83777 | -$425619 | $833782 | -$780021 | $3.2M | $3.7M | -$3.7M | $1.8M |
| Operating Cash Flow | -$112197 | -$716385 | -$3.6M | -$7.3M | -$13.5M | -$10.6M | -$14.1M | -$17.1M | -$13.8M |
| Capital Expenditure | -$3 | $5 | -$20120 | -$17945 | -$5748 | -$4422 | -$3901 | -$4188 | -$18175 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -$2043 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free Cash Flow | -$112197 | -$716385 | -$3.6M | -$7.3M | -$13.5M | -$10.6M | -$14.1M | -$17.1M | -$13.8M |
Growth & Margins (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income Growth (YoY) | -1304.1% | +47.5% | -143.9% | -53.3% | -5.4% | -23.4% | +21.2% | -6.7% | |
| EPS Growth (YoY) | -3271.0% | +47.5% | -141.5% | +3.4% | +32.0% | +55.4% | +99.7% | +92.3% | |
| Shares Change (YoY) | +0.0% | +0.0% | +1.0% | +58.6% | +55.0% | +176.7% | +25264.9% | +1291.9% | |
| FCF Growth (YoY) | -538.5% | -398.8% | -105.3% | -84.6% | +22.0% | -33.9% | -21.0% | +19.2% | |
| Effective Tax Rate | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% |
Per-Share Data (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| FCF Per Share | $-6138.35 | $-39193.76 | $-195512.89 | $-397291.58 | $-462542.98 | $-232693.33 | $-112629.70 | $-537.39 | $-31.19 |
| Dividends Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares Outstanding (Basic) | $18 | $18 | $18 | $18 | $29 | $45 | $126 | $31853 | $443369 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Profitability
| Return on Equity | -204.25% |
| Return on Invested Capital | -92.94% |
| Return on Assets | -76.12% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 5.86 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -21.50 |
Key Ratios (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| P/E | -342.84 | -10.17 | -16.76 | -3.13 | -1.28 | -0.21 | -0.25 | -0.15 | -0.15 |
| P/B | -1284.38 | -136.86 | 8.55 | 2.12 | 2.80 | 0.40 | -1.08 | 0.37 | 0.51 |
| P/S | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Related companies: CMND · ENSC · GRI · KTTA · NLSP · OGEN · SILO
Explore sector: Healthcare · Biotechnology
More sections of CNSP: Overview · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks